UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices) |
(Zip Code) |
| Registrant’s telephone number, including area code |
| ( |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
ITEM 5.07. Submission of Matters to a Vote of Security Holders.
The annual meeting of the stockholders of Allied Healthcare Products, Inc. (the “Company”) was held on November 11, 2021. Proxies were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934. There was no solicitation in opposition to management’s nominees for Directors. The voting results are noted below.
ELECTION OF DIRECTORS
All nominees for Directors were elected with the following votes cast:
| For | Withheld | Broker Non-Votes | ||||
| Susan E. Deuser | 1,044,395 | 66,209 | 1,149,990 | |||
| Judith T. Graves | 1,044,387 | 66,217 | 1,149,990 | |||
| Joseph F. Ondrus | 1,057,034 | 53,570 | 1,149,990 | |||
| Joseph E. Root | 1,043,394 | 63,210 | 1,153,990 | |||
| John D. Weil | 1,035,535 | 75,069 | 1,149,990 |
Agenda Item 2, concerning the ratification of the appointment of RubinBrown LLP as the Company’s independent registered public accounting firm for fiscal 2022 was approved by the stockholders with the following votes cast:
| For | Against | Abstain | ||
| 2,168,895 | 88,543 | 3,155 |
Agenda Item 3, an advisory (non-binding) vote to approve our executive compensation was approved by the stockholders with the following votes cast:
| For | Against | Abstain | Broker Non-Votes | |||
| 948,749 | 152,807 | 9,048 | 1,149,991 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ALLIED HEALTHCARE PRODUCTS, INC. | |||
| Date: November 12, 2021 | By: | /s/ Daniel C. Dunn | |
| Daniel C. Dunn | |||
| Chief Financial Officer | |||